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Abstract
Background: Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, is a rare histological type of bladder
cancer similar to plasma cells and is an aggressive variant of urothelial carcinoma associated with a poor prognosis.
Case presentation: A 41-year-old Asian man was referred to our hospital due to macroscopic hematuria.
Cystoscopy detected a non-papillary tumor, and a transurethral resection of the bladder tumor revealed
pT1N0M0 bladder cancer. A pathological examination showed high-grade invasive urothelial carcinoma and a
component of signet ring cell carcinoma. A follow-up of the transurethral resection with radical cystectomy was
carried out, and a pathological examination showed infiltrating urothelial carcinoma, with partial features of the
plasmacytoid variant. We added chemotherapy treatment with gemcitabine and cisplatin for two cycles. Our
patient has been free from recurrence for 2 years.
Conclusions: We herein report the case of a patient with a plasmacytoid variant of urothelial carcinoma
controlled with radial cystectomy and subsequent chemotherapy.
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Background
Invasive urothelial carcinoma, lymphoma-like/plasma-
cytoid variant (PUC), is a rare histological type of
bladder cancer similar to plasma cells and is an ag-
gressive variant of urothelial carcinoma (UC) associ-
ated with a poor prognosis. The first report for PUC
was provided by Sahin et al.; to date, only approxi-
mately 100 cases of PUC have been reported in the
English literature [1–5]. We herein report a case of a
patient with plasmacytoid urothelial carcinoma that
was successfully controlled with chemotherapy follow-
ing radical cystectomy.
Case presentation
A 41-year-old Asian man was referred to our hospital due
to macroscopic hematuria. His past history included mid-
dle ear cholesteatoma and he had no smoking history.
Cystoscopy detected a non-papillary tumor, and a trans-
urethral resection of the bladder tumor (TUR-Bt) and a
magnetic resonance imaging (MRI) scan revealed
cT3N0M0 bladder cancer.
Laboratory data at the time of admission
The hematological and biochemical data showed no ab-
normal findings. A urinary analysis resulted in the fol-
lowing: pH 6.5, red blood cell count 10–19/high-power
field (HPF), white blood cell count 1–4/HPF, protein
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negative, and glucose negative. The urinary cytology was
class III.
Imaging findings
An MRI scan showed that the tumor extended over the
bladder, as seen in Fig. 1. No obvious distal and local
lymphadenopathy was observed on a non-contrast com-
puted tomography (CT) scan.
Operative procedure
Our patient underwent a TUR-Bt, and a pathological
examination revealed urothelial carcinoma (high-grade,
pT1, G2) and signet ring cell carcinoma was found in
a portion of the bladder tumor. Two months after the
TUR-Bt, a radical cystectomy was performed according
to the tumor grade of malignancy and the imaging
findings (Fig. 2).
Pathological findings
Grossly, the infiltrating neoplasm, measuring 25 × 20 mm
in size, was located in the bladder trigone. The pathological
stage was pT2bN0M0. Histologically, the neoplasm was
composed of isolated atypical cells that had relatively abun-
dant eosinophilic cytoplasm with eccentric nuclei, showing
moderate pleomorphism. Perinuclear pale regions were
occasionally seen. These features partly resembled plasma
cells (Fig. 3). The immunohistochemical profile of the
tumor cells was positive for keratin CAM5.2 and CK20,
but negative for CK7, CD56, chromogranin A, synaptophy-
sin, CD20, CD79a, kappa and lambda. Thus, the diagnosis
of infiltrating high-grade urothelial carcinoma, plasmacy-
toid variant, was made. Plasma cells have a similar form to
signet ring cells, thus it is difficult to distinguish these cells.
However, plasma cells frequently show CD138 positivity,
which may be useful for discriminating between the two
types of cells.
a b
Fig. 1 Magnetic resonance imaging findings in (a) T2-weighted and (b) diffusion-weighted images. The mass was believed to be invasive outside
of the bladder wall (arrow)
Fig. 2 A surgical specimen from the radical cystectomy. The tumor
was located in the bladder trigone (arrow)
Fig. 3 Hematoxylin and eosin stain. Plasmacytoid urothelial carcinoma
was characterized by isolated cells with uneven nuclear distribution.
Invasive plasma cell was founded sparsely (enlarged part of image)
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Immunohistochemistry for PD-1 and PD-L1
An immunohistochemical analysis was performed on
5-μm-thick sections. The slides were dewaxed with xylene
and hydrated with gradient ethanol, and microwaved at
the high level for 2 minutes and then at the medium-low
level for 30 minutes for heat antigen retrieval (Target
Retrieval Solution pH 9, Dako, Carpinteria, CA, USA).
After 3 % hydrogen peroxidase blocking, the samples were
incubated overnight at 4 °C with a primary antibody
to PD-1 (dilution 1:50, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or PD-L1 (dilution 1:50, Santa Cruz
Biotechnology). The slides were then treated with a broad-
spectrum secondary antibody (Invitrogen, Grand Island,
NY, USA) and washed (Envision FLEX Wash Buffer,
Dako). After diaminobenzidine staining, the slides were
counterstained with hematoxylin, dehydrated with gradient
ethanol and xylene, and then sealed. There were no posi-
tive finding (Fig. 4).
Postoperative course
Two months after the total cystectomy, adjuvant chemo-
therapy with gemcitabine and cisplatin was administered
(G: 2,000 mg/m2, C: 63 mg/m2). We used the following
dosing schedule: day 1 G: 1,000 mg/m2, day 2 C: 63 mg/m2,
and day 8 G: 1,000 mg/m2 that was administered in
two cycles. No adverse event was observed. We followed
up our patient with cytology and a CTscan every 3 months.
Our patient has not experienced any recurrence of bladder
cancer for 2 years following the radical cystectomy.
Discussion
PUC is a rare histological type of bladder cancer similar
to plasma cells and is an aggressive variant of UC associ-
ated with a poor prognosis [6]. The first case of PUC
was reported by Sahin et al.; to date, only approxi-
mately100 cases of PUC have been reported in the
English literature [1–3, 5]. Most patients were in their
60s; the male-to-female ratio was 9:1. This variant is
typically diagnosed at an advanced pathological stage
(64 % pT3, 23 % pT4), showing metastases in 60 % of
the patients [3]. This tumor initially presents as a high-
grade, high-stage lesion, and diffusely invades the bladder
wall; however, patients have no specific symptoms, which
can lead to a delayed diagnosis and poor prognosis.
Furthermore, PUC is difficult to differentiate from sig-
net ring cell carcinoma of the urinary bladder due to over-
lap in the clinical and morphological presentation [4]. In
the present case, the initial diagnosis was signet ring cell
carcinoma, thus we performed a radical cystectomy be-
cause of the poor prognosis. However, the subsequent
pathological examination revealed infiltrating high-grade
urothelial carcinoma with partial features of the plasmacy-
toid variant, thus we administered chemotherapy.
Most urological guidelines recommend adjuvant
cisplatin-based chemotherapy as the therapy of choice in
locally advanced bladder cancer. However, it has been re-
ported that tumors with variant histology are associated
with a higher risk of progression than conventional high-
grade UC. Keck et al. reported that patients suffering from
PUC have the worst clinical outcome regarding overall
survival compared to conventional UC [7]. We searched
for other cases of PUC that were treated with cystectomy
and chemotherapy. Almost all cases were treated with
cystectomy and adjuvant chemotherapy. All cases were at
an advanced stage, and the chemotherapy consisted of
methotrexate, vinblastine, doxorubicin and cisplatin (M-
a b
Fig. 4 Immunohistochemistry for PD-1 (a) and PD-L1 (b) expression. There was no positive expression in both PD-1 and PD-L1
Table 1 The cases of PUC that were treated with cystectomy
and adjuvant chemotherapy
First author TNM stage Chemotherapy Outcome OS
Kohno [12] T4N0M0 M-VAC×2 Survival 18 m
Kawashima [13] T3aN0M0 M-VAC×2 Survival 11 m
Fritsche [14] T4bN2M0 GC×4 Survival 16 m
T4aN0M0 GC×5 Death 29 m
Soylu [15] T2bNxM0 5FU+leucovorin Death 18 m
Aldousari [16] T3bN0M0 GC Death 6 m
Hayashi [17] T4bN0M0 GC×2 Death 9 m
Present case T2bN0M0 GC×2 Survival 26 m
PUC invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, TNM tumor-
node-metastasis, OS overall survival, M-VAC methotrexate, vinblastine, doxorubicin
and cisplatin, GC gemcitabine and cisplatin, 5FU 5-fluorouracil, m months
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VAC) or GC. Cystectomy and adjuvant chemotherapy
with GC was relatively effective for the management of
PUC in terms of overall survival (Table 1). Furthermore,
Kaimakliotis et al. reported that the management of PUC
should be aggressive and that cystectomy should be per-
formed at all stages [8]. They also reported that although
it is unclear whether PUC is independently associated
with a poor prognosis, the prognosis in PUC is poor due
to the higher stage at the time of diagnosis [9].
Recently, an anti-PD-L1 drug was found to have a rapid
and ongoing response in patients with urothelial carcinoma
in a phase 1 study. Interestingly, this drug showed higher
efficacy in patients whose tumor-infiltrating cells showed
high levels of PD-L1 expression [10]. Boorjian et al.
reported that higher PD-L1 expression in tumor cells
was associated with the presence of advanced disease in
patients with urothelial carcinoma and that it was corre-
lated with a poor prognosis after radical cystectomy [11].
In our case, the tumor did not express PD-1 or PD-L1.
Although we predicted a poor prognosis for this vari-
ant, the tumor was successfully treated with a combin-
ation of radical cystectomy and adjuvant chemotherapy,
and our patient has remained free of any sign of recur-
rence of bladder cancer for 2 years after the operation.
Conclusions
We herein described the case of a patient with PUC con-
trolled with chemotherapy following radical cystectomy.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
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view by the Editor-in-Chief of this journal.
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